InvestorsHub Logo
Followers 2543
Posts 250735
Boards Moderated 34
Alias Born 05/06/2014

Re: None

Wednesday, 04/22/2015 10:47:48 PM

Wednesday, April 22, 2015 10:47:48 PM

Post# of 7349
$PMCB Clinical Milestones Abound for PharmaCyte Biotech in 2015

BALTIMORE, Mar. 30, 2015 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.

In the article on the Company, analyst Rob Goldman outlines the impact of upcoming milestones:

"In an era when small biotech companies may only launch one trial a year, having three, high profile, abdominal cancer trial events to look forward to this year could put PharmaCyte Biotech on the map. As a result, many investors believe these events will take the Company's profile and valuation to a new level, since it is so rare that a small biotech would launch three separate clinical trials in such short order. Moreover, the initiation of any trial, preclinical or late stage, can be a harbinger of potential product development success, depending upon the trial's outcome."

Goldman also noted, "The most highly anticipated event is a Phase 2b trial in Australia where PharmaCyte Biotech's pancreatic cancer treatment will be compared "head-to-head" with the best available chemotherapy (Abraxane(R) plus gemcitabine) for advanced pancreatic cancer, using its Cell-in-a-Box(R) live cell encapsulation technology. Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech's treatment in reducing the severe pain that occurs in patients with advanced pancreatic cancer and slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen."

"These landmark preclinical trials for abdominal cancers using the Company's platform technology were designed, in part, by the leading authority on pancreatic cancer, Dr. Daniel Von Hoff, and conducted by America's leading Contract Research Organization that specializes in preclinical and early-mid phase clinical trials in oncology. Having such distinguished authorities associated with these trials affirms the potential value and efficacy of the Company's technology and could result in future, fast-tracked clinical trials."

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was recently compensated by a third party in the amount of $4000 for investment research services and has been compensated $2500 for the publication of a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
rob@goldmanresearch.com

SOURCE Goldman Small Cap Research

http://www.prnewswire.com/news-releases/clinical-milestones-abound-for-pharmacyte-biotech-in-2015-300057455.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.